BUY Dr. Reddy's Laboratories Limited — Somil Mehta, Sharekhan
bySomil Mehta, SharekhanHorizon: NA (inferred 1–3 months)17 Sept 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
8 advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days
Advisor consensus · adjacent horizon·17 Sept · today
JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?
NewsEt-Markets·16 Sept · yesterday
Dr Reddy's Mexico API facility gets 2 observations in US FDA records assessment
NewsCnbc-Tv18·11 Sept · 5d ago
2 other SEBI-registered advisors have active short-term BUY calls on this stock
Advisor consensus · same horizon·11 Aug · 1mo ago
MACD below its signal line — bearish momentum
Technicals · macd·17 Sept · today
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NewsGoogle News·10 Sept · 1w ago
5 advisors have active long-term SELL calls on this stock
Advisor consensus · adjacent horizon·23 Jul · 2mo ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.